Articles with "idh1 mutation" as a keyword



Photo from wikipedia

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

Sign Up to like & get
recommendations!
Published in 2021 at "JAMA oncology"

DOI: 10.1001/jamaoncol.2021.3836

Abstract: Importance Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly improved with ivosidenib vs placebo.… read more here.

Keywords: trial; cholangiocarcinoma idh1; idh1 mutation; placebo ... See more keywords
Photo by kitera from unsplash

Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis

Sign Up to like & get
recommendations!
Published in 2018 at "Journal of Neuro-Oncology"

DOI: 10.1007/s11060-018-03047-1

Abstract: IntroductionIDH1 mutation has been identified as an early genetic event driving low grade gliomas (LGGs) and it has been proven to exerts a powerful epigenetic effect. Cells containing IDH1 mutation are refractory to epigenetical reprogramming… read more here.

Keywords: ipsc clones; regional chromosomal; idh1 mutation; grade gliomas ... See more keywords
Photo from wikipedia

Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma

Sign Up to like & get
recommendations!
Published in 2017 at "Journal of Clinical Neuroscience"

DOI: 10.1016/j.jocn.2017.01.007

Abstract: Isocitrate dehydrogenase 1 (IDH1) mutations in gliomas have been associated with a frontal lobe location and a greater proportion of noncontrast-enhancing tumour (nCET). The purpose of our study was to validate the utility of MRI… read more here.

Keywords: idh1 wildtype; glioblastoma; frontal lobe; idh1 ... See more keywords
Photo by fierysnake from unsplash

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism

Sign Up to like & get
recommendations!
Published in 2018 at "Journal of Thrombosis and Haemostasis"

DOI: 10.1111/jth.14129

Abstract: Essentials Risk stratification for venous thromboembolism (VTE) in patients with brain tumors is challenging. Patients with IDH1 wildtype and high podoplanin expression have a 6‐month VTE risk of 18.2%. Patients with IDH1 mutation and no… read more here.

Keywords: mutation podoplanin; podoplanin; idh1 mutation; podoplanin expression ... See more keywords
Photo from wikipedia

CT-based radiogenomic signature to identify isocitrate dehydrogenase (IDH)1/2 mutations in advanced intrahepatic cholangiocarcinoma.

Sign Up to like & get
recommendations!
Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.4081

Abstract: 4081 Background: IDH1/2 mutations have a high prevalence (20%) in intrahepatic cholangiocarcinoma (iCCA) and can be associated with therapeutic benefit from IDH inhibitors. Radiomics, a developing field within imaging, has shown its ability to discriminate… read more here.

Keywords: intrahepatic cholangiocarcinoma; idh1 mutation; signature; radiogenomic signature ... See more keywords
Photo from wikipedia

IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme

Sign Up to like & get
recommendations!
Published in 2018 at "Oncotarget"

DOI: 10.18632/oncotarget.24536

Abstract: Introduction Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor characterized by pathological vascularization. Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) were observed in GBM. We aimed to assess the intra-tumor… read more here.

Keywords: gbm; glioblastoma multiforme; idh1 mutation; expression ... See more keywords
Photo from wikipedia

Simplified Perfusion Fraction from Diffusion-weighted Imaging in Preoperative Prediction of IDH1 Mutation in WHO Grade II–III Gliomas: Comparison with Dynamic Contrast-enhanced and Intravoxel Incoherent Motion MRI

Sign Up to like & get
recommendations!
Published in 2020 at "Radiology and Oncology"

DOI: 10.2478/raon-2020-0037

Abstract: Abstract Background Effect of isocitr ate dehydrogenase 1 (IDH1) mutation in neovascularization might be linked with tissue perfusion in gliomas. At present, the need of injection of contrast agent and the increasing scanning time limit… read more here.

Keywords: diffusion; perfusion; idh1 mutation; mri ... See more keywords
Photo from wikipedia

Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas

Sign Up to like & get
recommendations!
Published in 2018 at "American Journal of Neuroradiology"

DOI: 10.3174/ajnr.a5421

Abstract: BACKGROUND AND PURPOSE: WHO grade II gliomas are divided into three classes: isocitrate dehydrogenase (IDH)-wildtype, IDH-mutant and no 1p/19q codeletion, and IDH-mutant and 1p/19q-codeleted. Different molecular subtypes have been reported to have prognostic differences and… read more here.

Keywords: codeletion; grade; idh1 mutation; lower grade ... See more keywords
Photo from wikipedia

Diagnostic performance of clinical properties and conventional magnetic resonance imaging for determining the IDH1 mutation status in glioblastoma: a retrospective study

Sign Up to like & get
recommendations!
Published in 2019 at "PeerJ"

DOI: 10.7717/peerj.7154

Abstract: Background Glioblastoma (GBM), the most malignant form of gliomas, is a relatively common primary brain tumor in adults. Preoperative identification of isocitrate dehydrogenase 1 (IDH1) mutations in GBM is of critical prognostic importance. The aim… read more here.

Keywords: idh1 mutation; diagnostic performance; performance; mutation status ... See more keywords